In this article included in The Globalisation of the Pharmaceutical Industry, the authors draw on their experience to develop lessons on how to establish a sustainable life sciences eco-system in middle-income countries (MICs) and low-income countries (LICs). They highlight the importance of different types of government policy (industrial policy, the regulatory framework, intellectual property, and improving access to medicines) and how success requires different stakeholders (public and private, international and national) to work together.
To read the article, click here.
Quantifying public and private investment in European biopharmaceutical research and development
CRA’s Annabelle Fowler, Andreas Maos, and Tim Wilsdon co-authored original research that explores the roles and contributions of public and private investments...